EP11.01-014 Optimizing Targetable Gene Screening by Sequential Multi-platform Detection Applied to Driver-negative mNSCLC Patients Detected by DNA-NGS

Abstract

Screening for targetable gene alteration is critical for patients with metastatic non-small cell lung cancer (mNSCLC) and is now mainly detected by next-generation sequencing (NGS) of DNA. For the patients without driver alteration, we estimated the value of additional sequential multi-traditional platform in the identification of targetable gene alteration in mNSCLC with limited tissue biopsy sample.